Skip to Content

Join the 'Plaque Psoriasis' group to help and get support from people like you.

Plaque Psoriasis News

Stigma Another Burden for Many With Psoriasis

Posted 6 Sep 2018 by Drugs.com

THURSDAY, Sept. 6, 2018 – Though psoriasis is not contagious, many Americans shun people with the skin condition, new research indicates. The study included a cross-section of about 400 Americans who viewed images of people with visible psoriasis. Large numbers wrongly thought psoriasis was contagious or only affects the skin, and about one-third said they wouldn't want to invite people with the ...

Could Psoriasis Patients Eat Their Way to Fewer Symptoms?

Posted 26 Jul 2018 by Drugs.com

THURSDAY, July 26, 2018 – A study of more than 3,500 French psoriasis patients found that the healthier their diet, the less severe their symptoms. Specifically, the closer an individual adhered to the nutritious "Mediterranean" diet, the less onerous their psoriasis became. This was true regardless of whether or not the patient was obese, the French researchers noted. The Mediterranean diet is ...

UCB Announces the Approval of Cimzia (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis

Posted 11 Jun 2018 by Drugs.com

Brussels, Belgium – 28th May, 07:00 CEST – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for Cimzia (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or pho ...

FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis

Posted 22 Mar 2018 by Drugs.com

MUMBAI, India and PRINCETON, N.J., March 21, 2018 /PRNewswire/ – Sun Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 and inhibits ...

Whites More Likely Than Others to Seek Help for Psoriasis

Posted 29 Dec 2017 by Drugs.com

THURSDAY, Dec. 28, 2017 – Among people with the skin disease psoriasis, could skin color play a role in whether or not they visit a dermatologist? An analysis of federal government health survey data from 2001 to 2013 found that black, Asian and other minorities are less likely than white people in the United States to see a doctor for treatment of the chronic inflammatory disease. The ...

FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

Posted 14 Dec 2017 by Drugs.com

December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* for all eligible indications of the reference product.1 The FDA has approved Ixifi as a ...

Severe Psoriasis May Make Diabetes Increasingly Likely

Posted 20 Nov 2017 by Drugs.com

MONDAY, Nov. 20, 2017 – People with the skin disease psoriasis are at increased risk for type 2 diabetes, and the more severe the psoriasis, the greater their risk, a new study finds. Researchers examined data on nearly 85,000 adults in the United Kingdom, including 8,100 who had psoriasis. Compared with people who did not have psoriasis, the risk for diabetes was 21 percent higher among those ...

Cyndi Lauper's Psoriasis Battle Shows Her 'True Colors'

Posted 25 Oct 2017 by Drugs.com

WEDNESDAY, Oct. 25, 2017 – With her pink tresses and eye-catching stage costumes, pop culture icon Cyndi Lauper was never one to hide. But that's exactly what she wanted to do when she developed psoriasis, which spread to most of her body and sapped her strength before the skin disorder was controlled. Appearing first on her scalp and later covering everything except her face, psoriasis struck ...

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis

Posted 18 Oct 2017 by Drugs.com

Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today’s approval marks a significant milestone for this age ...

Severe Psoriasis Linked to Higher Risk of Earlier Death

Posted 5 Sep 2017 by Drugs.com

TUESDAY, Sept. 5, 2017 – People with severe cases of the skin disease psoriasis appeared to have almost double the risk of dying during a four-year study than people without the condition, research suggests. But the increased death rate was only seen in those with psoriasis affecting more than 10 percent of their body surface area. For those with less-severe disease, the risk of dying early was ...

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Posted 30 Aug 2017 by Drugs.com

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** a ...

Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Posted 17 Jul 2017 by Drugs.com

Horsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine t ...

Promising Results for Ixekizumab Against Psoriatic Arthritis

Posted 26 May 2017 by Drugs.com

FRIDAY, May 26, 2017 – A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an out-of-control immune response. The disease affects about one in every 200 people and is often accompanied by the autoimmune skin disorder psoriasis. Psoriatic ...

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheu ...

Health Tip: Caring for Nail Psoriasis

Posted 17 Apr 2017 by Drugs.com

-- Nail psoriasis causes pitting, discoloration and thickening of the nails. So how to take care of your nails if you have the condition? Here are suggestions from the National Psoriasis Foundation: Trim your nails as short as you can, since longer nails are more prone to everyday damage. Protect your nails from injury, which can worsen psoriasis symptoms. When washing dishes, cleaning or ...

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Psoriasis

Related Drug Support Groups

Humira, methylprednisolone, Enbrel, Remicade, dexamethasone, Otezla, hydroxyurea, Cosentyx, Dovonex, view more... adalimumab, infliximab, Taltz, Ilumya, secukinumab, etanercept, Inflectra, Taclonex, apremilast, Ixifi, Cyltezo, Tremfya, Renflexis, Siliq, Amjevita, Erelzi, calcipotriene, Amevive, brodalumab, ixekizumab, Enstilar, Sernivo, Raptiva, betamethasone / calcipotriene, Calcitrene, guselkumab, Taclonex Scalp, Dovobet, efalizumab, tildrakizumab, alefacept, Sorilux